IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization
IL-6Ri may represent a promising therapeutic avenue for idiopathic pulmonary fibrosis, Parkinson's disease, and Type 2 diabetes.
Authors
- Chong Yau Fu (ORCID: https://orcid.org/0000-0002-2646-2778)
- L Wang
- Wenjiao Cai
Institutions
- Anqing City Hospital (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1452849
- Citations
- 11
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 3.11